All In Biotech

Drug Trial Radar · NCT06859099

Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

Long-term Extension Study to Evaluate the Safety and Efficacy of Riliprubart (SAR445088) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

300

Planned (sponsor's estimate)

Start

Apr 1, 2025

Primary completion

Oct 3, 2029

Study completion Oct 3, 2029

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Mar 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating polyneuropathy (CIDP) who have completed Part B in 1 of 3 parent studies (PDY16744, EFC17236, or EFC18156) and wish to continue treatment with riliprubart. Up to approximately 300 participants will be enrolled to continue receiving treatment with riliprubart. The duration of participation for each participant will be up to approximately 4 years, including posttreatment follow-up. The treatment duration will be up to approximately 3 years. A participant who discontinues riliprubart treatment at any time during the study will be followed for safety for a minimum of 55 weeks after the last dose of riliprubart received.

Conditions

  • Polyneuropathy, Inflammatory Demyelinating, Chronic

Interventions

  • Riliprubart Prefilled Pen (PFP)Drug

    Pharmaceutical form: Solution Route of administration: Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants having any AEs, SAEs, adverse events leading to treatment discontinuation, AESIs, and potentially clinically significant abnormalities (PCSAs) in safety laboratory tests, ECGs, and vital signs during the study periodTime frame: Up to End of Study (approx. 4 years)

Locations

63 sites in 24 countries. Site status is shown where the registry gives one.

  • Alabama Neurology Associates- Site Number : 8400019

    Homewood, Alabama

  • Honor Health Scottsdale Osborn Medical Center- Site Number : 8400014

    Scottsdale, Arizona

  • University of Kansas Medical Center- Site Number : 8400010

    Kansas City, Kansas

  • Columbia University Irving Medical Center- Site Number : 8400003

    New York, New York

  • Penn Medicine: University of Pennsylvania Health System- Site Number : 8400022

    Philadelphia, Pennsylvania

  • Investigational Site Number : 0320003

    Buenos Aires, Argentina

  • PSEG Centro de Pesquisa Clínica- Site Number : 0760009

    São Paulo, Brazil

  • L2IP - Instituto de Pesquisas Clínicas- Site Number : 0760006

    Brasília, Federal District, Brazil

  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760004

    Ribeirão Preto, São Paulo, Brazil

  • Investigational Site Number : 1000002

    Blagoevgrad, Bulgaria

  • Investigational Site Number : 1240001

    Gatineau, Quebec, Canada

  • Investigational Site Number : 1240002

    Québec, Quebec, Canada

  • Investigational Site Number : 1520003

    Lo Barnechea, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520002

    Puente Alto, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1560013

    Beijing, China

  • Investigational Site Number : 1560005

    Beijing, China

  • Investigational Site Number : 1560009

    Changsha, China

  • Investigational Site Number : 1560011

    Chengdu, China

  • Investigational Site Number : 1560002

    Fuzhou, China

  • Investigational Site Number : 1560012

    Guangzhou, China

  • Investigational Site Number : 1560014

    Hangzhou, China

  • Investigational Site Number : 1560001

    Shanghai, China

  • Investigational Site Number : 1560003

    Wuhan, China

  • Investigational Site Number : 1560006

    Wuhan, China

  • Investigational Site Number : 1560004

    Xi'an, China

  • Investigational Site Number : 2030004

    Brno, Czechia

  • Investigational Site Number : 2030001

    Prague, Czechia

  • Investigational Site Number : 2080002

    Aarhus, Denmark

  • Investigational Site Number : 2080001

    Copenhagen, Denmark

  • Investigational Site Number : 2500007

    Bordeaux, France

  • Investigational Site Number : 2500001

    Le Kremlin-Bicêtre, France

  • Investigational Site Number : 2500002

    Marseille, France

  • Investigational Site Number : 2500005

    Montpellier, France

  • Investigational Site Number : 2500004

    Paris, France

  • Investigational Site Number : 2760002

    Göttingen, Germany

  • Investigational Site Number : 2760003

    Münster, Germany

  • Investigational Site Number : 2760004

    Tübingen, Germany

  • Investigational Site Number : 3800005

    Pavia, Italy

  • Investigational Site Number : 3800007

    Pisa, Italy

  • Investigational Site Number : 3800003

    Genoa, Genova, Italy

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.